C4 Therapeutics, Inc. 8-K

What Happened
C4 Therapeutics, Inc. filed a Form 8‑K on January 14, 2026 (Item 7.01) to disclose a press release outlining company milestones through 2028 and recent achievements. The press release was furnished as Exhibit 99.1 to the filing and the report was signed by CFO Kendra R. Adams. The disclosure was made under Regulation FD.

Key Details

• Filing date: January 14, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Press release furnished as Exhibit 99.1; Exhibit 104 (Cover Page Interactive Data/Inline XBRL) also included.
• Press release highlights milestones and expected progress through 2028 (company roadmap/timeframe).
• Report signed by Kendra R. Adams, Chief Financial Officer and Treasurer.

Why It Matters
This 8‑K is a corporate update—not a financial results filing. It provides a public timeline of clinical and development milestones that may affect investor expectations about future program progress and valuation. The filing does not report earnings, revenue, quarterly results, a CEO change, or any merger/acquisition—investors should read the attached press release (Exhibit 99.1) for program‑level details and timelines.